Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center

home / authors / alexander-drilon-md-memorial-sloan-kettering-cancer-center

Articles

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
July 1st 2021

Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.

Read More

Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers

Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers

Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
July 1st 2021

Alexander Drilon, MD presents updated results from a pooled analysis of TRK fusion-positive cancers treated with larotrectinib from the 2021 American Society of Clinical Oncology annual meeting.

Read More

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Development of KRAS G12C-Targeted Therapy in NSCLC

Development of KRAS G12C-Targeted Therapy in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Systemic Therapy for KRAS+ Advanced NSCLC

Systemic Therapy for KRAS+ Advanced NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Counseling Patients With NSCLC When KRAS is Detected

Counseling Patients With NSCLC When KRAS is Detected

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Testing for KRAS Mutations in NSCLC

Testing for KRAS Mutations in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

KRAS Mutations in Solid Tumors

KRAS Mutations in Solid Tumors

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Current Management of Oncogene-Driven NSCLC

Current Management of Oncogene-Driven NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More